Objectives: Voriconazole exhibits highly variable, non-linear pharmacokinetics and is associated with a narrow therapeutic range. This study aimed to investigate the population pharmacokinetics of voriconazole in adults, including the effect of CYP2C19 genotype and drug -drug interactions.
Introduction
The triazole antifungal voriconazole exhibits broad-spectrum antifungal activity and is indicated in the treatment of a range of pathogenic and opportunistic mycoses. 1 Highly variable, non-linear pharmacokinetics complicate the clinical use of voriconazole, with hepatic metabolism occurring primarily via the polymorphic drug-metabolizing enzyme CYP2C19 and, to a lesser extent, CYP3A4 and CYP2C9. 2 Drug interactions, patient age and CYP2C19 genotype have been found to contribute to the pharmacokinetic variability observed with voriconazole. 2, 3 Since FDA and European Medicines Agency (EMA) approval in 2002, a growing number of studies have investigated exposureresponse relationships with voriconazole. These studies have identified a relationship between low voriconazole exposure and higher rates of treatment failure, in addition to higher rates of neurotoxicity at higher exposure, establishing a narrow therapeutic range for voriconazole. 4 -10 Notably, a recent randomized, controlled trial demonstrated improved treatment outcomes in patients who received therapeutic drug monitoring of voriconazole, 11 affirming the importance of optimizing voriconazole exposure in patients.
Population pharmacokinetic analyses are a valuable technique for characterizing the pharmacokinetics of medicines, identifying and quantifying sources of patient-related (demographic and genotypic) and clinical (drug interactions and disease-related) pharmacokinetic variability, and providing dose recommendations for clinical practice based on model simulations. Using a range of pharmacokinetic studies undertaken in healthy volunteers and patients, this study aimed to characterize the pharmacokinetics of voriconazole in adults and evaluate the influence of demographic, genotypic and clinical covariates on voriconazole exposure using a population pharmacokinetic approach. Furthermore, this study aimed to investigate the ability of current dosing recommendations for voriconazole to achieve efficacious and safe systemic exposure within the therapeutic range using simulations from the final pharmacokinetic model.
Methods

Pharmacokinetic data and participants
Pharmacokinetic data and relevant clinical data from six voriconazole studies in healthy volunteers or patients receiving voriconazole for the treatment or prophylaxis of fungal infections were available for analysis. Information on study design, population, pharmacokinetic data and participant demographics is included in Table 1 . Further details on these studies have been described previously. 3,4,12 -15 Population pharmacokinetic modelling
The pharmacokinetic data were analysed using non-linear mixed effects modelling with NONMEM 7.2 (Globomax LLC, Hanover, MD, USA 
Structural model and interindividual variability (IIV)
Pharmacokinetic models incorporating either one or two compartments with first-order oral absorption and linear, non-linear (MichaelisMenten) or parallel linear and non-linear elimination were investigated. An improvement in model fit with the addition of an oral absorption lag time was evaluated. Models were initially developed with richly sampled intravenous and oral voriconazole pharmacokinetic data (studies 1 -3, 5 and 6; Table 1 ); sparsely sampled concentration -time data were then incorporated into the model (study 4, Table 1 ) with appropriate goodness-of-fit testing.
IIV in voriconazole pharmacokinetic parameters was evaluated using exponential error models. A logit model was used for bioavailability to ensure physiologically plausible individual estimates not exceeding 
Covariate model
Participant-specific covariates such as body weight, age and sex, as well as potential drug -drug interactions, including co-administered proton pump inhibitors (pantoprazole, omeprazole, esomeprazole, rabeprazole), phenytoin, rifampicin, short-term ritonavir (300 mg twice daily for 2 days), St John's wort and glucocorticoids, were investigated. Only biologically plausible parameter -covariate relationships were explored. Continuous covariates were examined in the first instance using linear parametercovariate relations, with the exception of body weight on V max , which was also tested using allometric scaling with an exponent of 0.75. Categorical covariates were parameterized as a multiplicative effect on the associated structural parameter. A full model, including all potential parameter -covariate relationships, was developed from the final covariate-free model; covariates were then tested by individual deletion from the full model. Parameter -covariate relationships that resulted in a significant increase in objective function value (OFV) (≥10.83) upon deletion from the full model were retained in the final model.
Model selection and validation
Model development and selection were guided by goodness-of-fit criteria, including significant decreases in OFV between nested models, goodness-of-fit plots, precision of parameter estimates and visual predictive checks (VPCs). A decrease of 3.84 in OFV (P, 0.05) for one degree of freedom was considered statistically significant. 16 Prediction-and variability-corrected VPCs (pvcVPCs) were used for model validation. 17 Similar to VPCs, pvcVPCs allow a graphical assessment of the predictive performance of a model by comparing model simulations with observed data in terms of central trend and variability, but differ in that both model simulations and observed data are normalized to correct for differences arising from independent variables (e.g. differences in dose, time or covariates) as well as the typical population variability in each bin. 17 One thousand simulated datasets of individuals from the original dataset were compared with prediction-and variability-corrected observed concentrations. Bootstrapping procedures were not feasible due to very long model runtimes.
CYP2C19 genotype
Information on CYP2C19 genotype was available for participants from five of the six studies included in the analysis (Table 1) . Participants were assigned a CYP2C19 phenotype based on the presence of loss-of-function (LoF) (CYP2C19*2) or gain-of-function (GoF) alleles (CYP2C19*17): heterozygous ultra-rapid metabolizer (HUM; CYP2C19*1/*17), extensive metabolizer (EM; CYP2C19*1/*1), heterozygous extensive metabolizer (HEM; CYP2C19*1/*2), poor metabolizer (PM; CYP2C19*2/*2) or unknown phenotype (CYP2C19*2/*17) (adapted from Scott et al.
18
). Among the five studies where CYP2C19 genotype was known, no participants were identified with other CYP2C19 LoF alleles (*3 allele) or with two GoF alleles (CYP2C19*17/*17).
Dosing simulations and effect of covariates
Using the $SIM command with NONMEM, dosing simulations with parameter estimates from the final voriconazole pharmacokinetic model were performed to assess the probability of voriconazole trough concentration target attainment, defined as a trough concentration between 2 and 5 mg/L. 4 Simulations were stratified by CYP2C19 phenotype. Dosing simulations were designed to examine trough concentrations following an oral or intravenous loading dose on day 1 of treatment (400 mg twice daily) as well as on day 7 of treatment following 200 mg twice daily, 300 mg twice daily or 400 mg twice daily oral or intravenous voriconazole dosing (each with a loading dose for the first two doses). A range of voriconazole concentration cut-off values (1, 1.5, 2 and 5 mg/L) were investigated to examine the probability of sub-or supratherapeutic concentrations with each dose regimen. One thousand patient simulations were performed for each dose regimen.
The influence of significant covariates in the final model on voriconazole trough concentrations was also investigated. One thousand patient simulations stratified by CYP2C19 phenotype were performed to assess the impact of each covariate on voriconazole trough concentrations on day 7 of treatment, following standard oral voriconazole dosing (400 mg twice daily for two doses followed by 200 mg twice daily). Simulated trough concentrations with and without each covariate were compared with the therapeutic range for voriconazole.
Results
Model development and validation
Three thousand three hundred and fifty-two voriconazole concentration measurements from a total of 240 participants were included in this analysis. A two-compartment pharmacokinetic model with first-order oral absorption with an absorption lag time and Michaelis -Menten elimination adequately described the dataset; models incorporating linear elimination resulted in significant increases in OFV whereas models incorporating parallel linear and non-linear elimination did not improve goodness of fit over non-linear elimination alone. A combined proportional and additive residual error model was used. Goodness-of-fit plots and pvcVPCs used throughout model development indicated acceptable model fit (data not shown). The pvcVPCs of the final model ( Figure 1 ) indicated good predictive performance, with acceptable agreement between prediction-and variabilitycorrected observed data and model-simulated CIs for the median and 5th and 95th percentiles.
Parameter estimates and associated standard errors for the structural model, IIV and residual variability from the final model are shown in Table 2 . High IIV in voriconazole pharmacokinetics was observed, particularly in the Michaelis -Menten constant (K m ) (CV% 64.5) and volume of distribution in the central compartment (83.4%). Voriconazole bioavailability was estimated to be 94% with IIV of 36.7%.
Voriconazole V max was found to be significantly higher in healthy volunteers compared with patients receiving voriconazole. The extent of this effect was characterized using a categorical covariate (Table 3) . A difference in voriconazole elimination between single-dose and multiple-dose data was also investigated; however, this resulted in numerical difficulties with the model, possibly due to co-linearity with the covariate differentiating healthy volunteers and patients.
Effect of CYP2C19 genotype
The effect of CYP2C19 genotype on voriconazole elimination was estimated using a binary categorical CYP2C19 phenotype, with participants allocated to a phenotype group based on the presence of one or more CYP2C19 LoF alleles. The difference in V max in participants with an HEM or PM phenotype for CYP2C19 was estimated as a multiplicative difference compared with V max in participants with an EM or HUM phenotype. To prevent potential Voriconazole population pharmacokinetics 1635 JAC bias in the estimated effect of CYP2C19 function on voriconazole, an additional parameter was estimated in participants where CYP2C19 genotype was not known (study 4). 19 Participants with one or more CYP2C19 LoF alleles had, on average, a 41.2% lower V max for voriconazole compared with participants with no LoF alleles (Table 3) . 
Dosing simulations and target attainment stratified by CYP2C19 phenotype
The probability of voriconazole target trough concentration attainment stratified by dosing regimen and CYP2C19 phenotype is shown in Table 4 . Among patients with a CYP2C19 EM/HUM phenotype, oral voriconazole loading doses on day 1 resulted in trough concentrations ≥2 mg/L in 33% of patients. Standard oral dosing of 200 mg of voriconazole twice daily resulted in a small decline in this proportion by day 7 of therapy (28%). Higher-dose oral regimens (voriconazole at 300 mg twice daily or 400 mg twice daily) were associated with a higher probability of target attainment (51% and 70%, respectively); however, the probability of supratherapeutic concentrations ≥5 mg/L also increased (21% and 41%). Lower voriconazole trough concentration targets (1 or 1.5 mg/L) resulted in higher probabilities of target attainment, as did the use of intravenous rather than oral voriconazole dosing regimens.
Voriconazole target attainment was substantially higher among patients with a PM/HEM phenotype for CYP2C19, as was the risk of trough concentrations ≥5 mg/L associated with the possibility of voriconazole adverse effects. Oral voriconazole loading doses on day 1 were associated with a 59% probability of trough concentrations ≥2 mg/L on day 1, with this figure increasing to 63% on day 7 following 200 mg twice daily dosing; however, 29% of patients would be expected to achieve concentrations ≥5 mg/L. Higher voriconazole dose regimens were associated with a very high probability of trough concentrations ≥5 mg/L among patients with a PM/HEM phenotype for CYP2C19, with a 57% and 77% probability for 300 mg twice daily oral and intravenous regimens, and 76% and 93% for 400 mg twice daily oral and intravenous regimens.
The predicted median voriconazole concentration -time profile over the first 7 days of treatment from 1000 simulated patients following standard oral dosing, stratified by CYP2C19 phenotype, is shown in Figure 2 . Clear evidence of the saturation of voriconazole metabolism was predicted among a significant proportion of patients with a CYP2C19 PM/HEM phenotype.
Effects of covariates on voriconazole pharmacokinetics
Significant covariates included in the final pharmacokinetic model for voriconazole are shown in Table 3 . Co-administration of phenytoin or rifampicin, St John's wort, methylprednisolone, dexamethasone and prednisone or prednisolone was associated with significant increases in the estimated voriconazole V max , whereas short-term ritonavir reduced V max . Most covariate effects were estimated with good precision; lower precision was observed for co-administration of dexamethasone (relative standard error 77.7%). The effect of these medicines on predicted voriconazole trough concentrations in relation to the therapeutic range, stratified by CYP2C19 phenotype, is shown in Figure 3 . Co-administration of phenytoin, rifampicin and St John's wort was associated with large reductions in voriconazole exposure, with most patients achieving trough concentrations far below the therapeutic range, particularly among those with an EM/ HUM phenotype for CYP2C19. A more moderate reduction in voriconazole exposure was observed with glucocorticoid co-administration. Short-term ritonavir co-administration was associated with large increases in voriconazole trough concentrations, increasing the probability of concentrations exceeding the therapeutic range, particularly among patients with a PM/HEM phenotype for CYP2C19.
Tested parameter-covariate relationships that did not result in a significant increase in OFV (≥10.83) when removed from the full 
Discussion
This study provides a comprehensive analysis of the population pharmacokinetics of voriconazole and the influence of a number of significant drug -drug interactions, with dosing simulations providing the first report of voriconazole target attainment stratified by CYP2C19 phenotype. CYP2C19 genotype is a key intrinsic determinant of voriconazole exposure. 3, 20, 21 This study demonstrates that among patients without CYP2C19 LoF alleles, a majority are predicted to require higher dosing, of at least 300 mg twice daily, to achieve recommended trough voriconazole concentrations (≥2 mg/L). Conversely, patients with CYP2C19 LoF alleles have substantially increased voriconazole exposure, with a significant proportion (29% -39%) at risk of potentially toxic voriconazole concentrations of ≥5 mg/L with 200 mg twice daily dosing. It is important to note that no individuals with known homozygous GoF alleles (CYP2C19*17/*17) were included in this analysis. Voriconazole exposure in individuals with this genotype is yet to be investigated, but would be expected to be further reduced compared with heterozygous ultra-rapid metabolizers and extensive metabolizers. 22, 23 Despite this, genotype information is not typically available in clinical practice and, if investigated, may not become available until after the patient has begun treatment. While routine genotyping of CYP2C19 may be of use for voriconazole, particularly in determining initial dosing, overlap between and high variability in exposure within phenotype groups is observed with voriconazole, Day 7 dosing regimens included a loading dose of 400 mg of voriconazole twice daily for two doses on day 1. Intravenous regimens were simulated as a 1, 1.5 and 2 h intravenous infusion for the voriconazole 200 mg, 300 mg and 400 mg regimens, respectively. Dolton et al.
limiting the utility of CYP2C19 genotype in predicting dose requirements in an individual patient. In the context of the narrow therapeutic range associated with voriconazole, these findings support the crucial role of therapeutic drug monitoring of voriconazole in ensuring efficacious and safe systemic exposure. Several population pharmacokinetic analyses have recently been published for voriconazole in adults, each using different methods to characterize voriconazole elimination. 9, 24, 25 As in the present study, Hope 25 described voriconazole elimination using a Michaelis -Menten model using data from healthy volunteers and patients, whereas Pascual et al. 9 used linear elimination in their analysis of voriconazole patient data. The model developed by Friberg et al. 24 included data from immunocompromised children and adolescents as well as healthy adults, and used a parallel linear and non-linear elimination model. Figure 4 provides a comparison of the predicted clearance with increasing voriconazole concentration from the present study and with these previously published models. 9,24 -26 As demonstrated in Figure 4 , the parameter estimates reported by Friberg et al. 24 predict significantly higher voriconazole clearance than was observed in patients in this study, irrespective of CYP2C19 phenotype. This finding may be attributable to the healthy volunteer rather than patient adult study population used by Friberg et al.;
24 significantly faster elimination among healthy volunteers compared with patients was also identified in the present analysis. Furthermore, a similar finding is apparent in the FDA Clinical Pharmacology and Biopharmaceutics Review of voriconazole in data submitted by the original manufacturer in 2002. Among pooled Phase I data from 402 healthy volunteers, the median of average steady-state voriconazole concentrations (presumably untimed) was 0.95 mg/L; the median concentration among 1053 patients from Phase II/III studies was 2.49 mg/L, 27 suggesting slower voriconazole elimination among patients.
No relationship between body weight and voriconazole pharmacokinetics was identified in this analysis. This finding has been reported in other analyses, 9, 25 including the original population pharmacokinetic analysis submitted to the FDA by the manufacturer, 27 and does not support the use of weight-based dosing regimens with voriconazole in adults. This result is reinforced by increasing evidence of high voriconazole exposure in obese patients dosed according to actual body weight, 28 and similar exposure in obese and non-obese individuals when weightindependent voriconazole dosing is used. 29 In adult patients weighing ,40 kg, the manufacturer recommends the oral maintenance dose should be halved, 30 mirroring the dosing regimen used in Phase II/III studies. 27 In this analysis, only one individual weighed ,40 kg, precluding an analysis of voriconazole exposure in patients weighing ,40 kg. Therefore, this study supports the use of weight-independent dosing regimens of voriconazole in adult patients weighing ≥40 kg.
Voriconazole oral bioavailability was estimated to be 94% in this analysis, although significant IIV was observed. Voriconazole bioavailability in healthy volunteers has been estimated between 83% and 96%, 3, 21, 30 with other population analyses reporting values of 86%, 64% and 63%. 9, 24, 25 Despite high bioavailability, the risk of subtherapeutic voriconazole exposure is higher with oral dosing regimens ( Table 4 ), suggesting that increased monitoring of voriconazole concentration during intravenous to oral switch is prudent.
A number of drug -drug interactions significantly influenced voriconazole elimination in this analysis. Phenytoin, rifampicin and St John's wort were associated with a substantial reduction in voriconazole exposure, with glucocorticoid co-administration associated with a smaller reduction in exposure. We previously identified an association between glucocorticoid co-administration and lower voriconazole concentrations, with in vitro and some in vivo evidence supporting an inductive effect of glucocorticoids on CYP2C19 and/or CYP3A. 4,31 -33 A limitation of the effect of phenytoin, rifampicin and glucocorticoids on voriconazole elimination is that these medicines were co-administered primarily among patients with sparse pharmacokinetic sampling (study 4), which may have affected the precision of these estimates, although some patients with more detailed sampling (study 6) were also co-administered glucocorticoids. Furthermore, the magnitude of interaction observed with rifampicin or phenytoin on voriconazole exposure is similar to that observed in crossover interaction studies.
30
Short-term ritonavir co-administration (300 mg twice daily for 2 days) was associated with significantly increased voriconazole exposure, as previously described in a study included in this analysis. 12 The effect of ritonavir on voriconazole pharmacokinetics is complex, and is both time and dose dependent. 12, 34 In a study of Voriconazole population pharmacokinetics longer-term ritonavir co-administration (400 mg twice daily for 20 days with voriconazole co-administered for 10 days), Liu et al. 34 observed an 82% reduction in mean voriconazole AUC, with a 39% reduction seen with low-dose ritonavir (100 mg twice daily). The increased voriconazole exposure observed with short-term ritonavir co-administration is likely due to inhibition of CYP3A by ritonavir, whereas the significantly decreased exposure seen with longer-term co-administration is attributable to potent induction of CYP2C19. 35 Taken together, these results indicate ritonavir may initially increase the risk of concentrationdependent adverse events with voriconazole; however, longerterm co-administration is likely to compromise voriconazole efficacy due to low systemic exposure.
The highly variable, non-linear pharmacokinetics and the prevalence of significant drug -drug interactions with voriconazole render empirical dose adjustment inaccurate and nonintuitive. Combined with the narrow therapeutic index, these factors support the potential benefit of a Bayesian feedback strategy to individualize dose, a concept that has been demonstrated in liver transplant recipients receiving oral voriconazole 36 and in a separate analysis with intravenous voriconazole. 37 However, a number of challenges remain in the application of computer-based forecasting strategies to the use of voriconazole. The most significant of these is likely to be the inherent difficulty of accurately estimating non-linear elimination (V max and K m ) in an individual patient in the clinical setting. Routine trough concentration monitoring will not necessarily identify a patient with saturated voriconazole elimination until more than one concentration measurement is available, revealing an ongoing and potentially rapid increase in trough concentrations. Furthermore, with standard voriconazole dosing many patients may display relatively linear pharmacokinetics due to concentrations remaining predominantly below K m , which would not provide sufficient individual information on V max and K m unless higher doses (with accompanying concentration sampling) were used to unmask saturable elimination. Future work will examine the feasibility and predictive performance of this model when used as part of a Bayesian feedback strategy for voriconazole.
Voriconazole is an important antifungal agent with challenging pharmacokinetics, a narrow therapeutic index and significant drug -drug interactions. In addition to characterizing the pharmacokinetics of voriconazole and the impact of a range of demographic and clinical covariates, this study demonstrates the wide variability in dose required to achieve efficacious and safe voriconazole exposure. In light of this, therapeutic drug monitoring is a crucial tool in managing the numerous challenges associated with voriconazole therapy. , 24 Hope 25 and Pascual et al. 9 For models incorporating non-linear or parallel linear and non-linear elimination, clearance was estimated from V max and K m as CL¼V max /(K m +C), where C¼voriconazole concentration. 26 a Friberg et al. 24 classified individuals with the CYP2C19*17 allele as ultra-rapid metabolizers (UM phenotype); it is not specified whether a distinction between individuals heterozygous and homozygous for the *17 allele was made (HUM versus UM phenotype), as was the case in the present study. Dolton et al. 
